1. The vinca alkaloids and the taxanes both act on beta-tubulin but bind at separate sites. To which site on beta-tubulin do the vinca alkaloids bind?
A) The taxane domain on the interior surface of the microtubule lumen
B) The colchicine domain at the interface between alpha-tubulin and beta-tubulin
C) The vinca domain, a site distinct from the taxane binding site
D) The GTP (guanosine triphosphate) exchange site on alpha-tubulin
E) The C-terminal tail of beta-III tubulin
ANSWER: C
Rationale:
Vinca alkaloids (vincristine, vinblastine, vinorelbine) bind the beta-tubulin subunit at the vinca domain, a site distinct from the taxane binding site. From this site they suppress dynamic instability at microtubule plus ends and, at higher concentrations, produce frank depolymerization. Because the vinca and taxane domains are physically separate, there is no inherent target-level cross-resistance between the two classes.
Option A: Option A is incorrect: the taxane domain on the interior microtubule lumen is where the taxanes and epothilones bind, not the vinca alkaloids.
Option B: Option B is incorrect: the colchicine domain is a separate tubulin site used by colchicine, not the vinca alkaloid binding site.
Option D: Option D is incorrect: the GTP exchange site relates to tubulin's intrinsic nucleotide handling and is not the vinca alkaloid pharmacologic target.
Option E: Option E is incorrect: the C-terminal tail of beta-III tubulin relates to isotype-based resistance, not the vinca binding site.
2. Taxanes and epothilones share a common binding site that differs from the vinca domain. Where do the taxanes and epothilones bind?
A) The taxane domain on beta-tubulin, located on the interior (luminal) surface of the microtubule
B) The vinca domain on beta-tubulin at the microtubule plus end
C) The exterior outer wall of alpha-tubulin near the plus end
D) The kinetochore-microtubule attachment plate
E) A site on gamma-tubulin within the centrosome
ANSWER: A
Rationale:
Taxanes (paclitaxel, docetaxel, cabazitaxel) and the epothilones bind the taxane domain on beta-tubulin, located on the interior (luminal) surface of the microtubule. Binding here stabilizes the polymer by reducing the off-rate of tubulin subunits and suppressing dynamic instability, locking microtubules in a non-dynamic state. Because the epothilones bind an overlapping region of this same domain, some beta-tubulin mutations that reduce taxane binding do not fully cross-resist the epothilones.
Option B: Option B is incorrect: the vinca domain is where the vinca alkaloids bind, not the taxanes.
Option C: Option C is incorrect: the taxane site is on the interior lumen of beta-tubulin, not the exterior wall of alpha-tubulin.
Option D: Option D is incorrect: the kinetochore attachment plate is a chromosomal structure, not a tubulin drug-binding site.
Option E: Option E is incorrect: gamma-tubulin nucleates microtubules at the centrosome and is not the taxane binding target.
3. Antimicrotubule agents act on a specific phase of the cell cycle, which determines the tumor populations they affect most. These drugs are best described as specific to which cell-cycle phase?
A) S phase, acting during DNA synthesis
B) G1 phase, acting before commitment to division
C) G2 phase, acting during preparation for mitosis but before spindle formation
D) M phase (mitosis), because the mechanism requires cells to enter and attempt mitosis
E) G0, acting on quiescent non-dividing cells
ANSWER: D
Rationale:
Antimicrotubule agents are M-phase (mitosis) specific. Their mechanism depends on disrupting the mitotic spindle while the cell is attempting to divide, sustaining the spindle assembly checkpoint and arresting the cell at mitosis until apoptosis ensues. Because cells must enter and attempt mitosis for the drugs to act, rapidly proliferating tumors that spend more time in mitosis are more vulnerable than slowly cycling tissue.
Option A: Option A is incorrect: S-phase specificity describes antimetabolites acting on DNA synthesis, not microtubule-targeting drugs.
Option B: Option B is incorrect: G1 is before the cell engages the spindle machinery these drugs target.
Option C: Option C is incorrect: although spindle assembly begins around the G2-to-M transition, the drugs exert their arrest during mitosis itself, when the spindle is active.
Option E: Option E is incorrect: these agents require active division and do not act on quiescent G0 cells.
4. Antimicrotubule agents arrest dividing cells by sustaining the activity of a specific mitotic checkpoint. Which checkpoint is held active by these drugs?
A) The G1/S restriction point governed by the retinoblastoma protein
B) The spindle assembly checkpoint (SAC), which monitors kinetochore attachment and tension
C) The G2/M DNA damage checkpoint governed by ATM/ATR kinases
D) The DNA replication origin licensing checkpoint
E) The intra-S-phase checkpoint that slows replication after DNA damage
ANSWER: B
Rationale:
Antimicrotubule drugs sustain the spindle assembly checkpoint (SAC). The SAC monitors whether every kinetochore is properly attached to spindle microtubules and under sufficient tension; while any kinetochore is unattached or improperly attached, the SAC inhibits the anaphase-promoting complex/cyclosome and blocks progression to anaphase. By disrupting microtubule dynamics, these drugs prevent proper attachment, keep the SAC active, and hold the cell in mitotic arrest until apoptosis occurs.
Option A: Option A is incorrect: the G1/S restriction point controls entry into S phase and is not the checkpoint these drugs engage.
Option C: Option C is incorrect: the G2/M DNA damage checkpoint responds to DNA damage via ATM/ATR, a different surveillance system.
Option D: Option D is incorrect: replication origin licensing is a pre-S-phase control unrelated to spindle attachment.
Option E: Option E is incorrect: the intra-S-phase checkpoint responds to replication stress, not to spindle microtubule attachment.
5. A feature of vincristine dosing distinguishes it from most other cytotoxic agents and contributes to the clinical risk of inadvertent overdose. Which statement correctly describes this feature?
A) Vincristine has a narrow bone marrow-based dose ceiling that forces frequent dose reductions
B) Vincristine dosing is capped strictly by renal clearance thresholds
C) Vincristine must be dose-reduced for every patient based on body surface area limits unique to the drug
D) Vincristine has a fixed maximum cumulative cardiac dose analogous to the anthracyclines
E) Vincristine has essentially no upper dose limit based on bone marrow tolerance, which makes inadvertent overdose a clinical risk
ANSWER: E
Rationale:
Because vincristine's dose-limiting toxicity is peripheral neurotoxicity rather than myelosuppression, it has essentially no upper dose ceiling based on bone marrow tolerance. The usual safety brake of marrow suppression that limits many cytotoxic agents does not apply, so an erroneously high dose is not flagged by the marrow, making inadvertent overdose a real clinical risk. This is why institutional dose caps and verification steps are emphasized for vincristine.
Option A: Option A is incorrect: vincristine is not limited by marrow tolerance, which is precisely the source of overdose risk.
Option B: Option B is incorrect: vincristine is hepatically metabolized via CYP3A4, and renal clearance thresholds do not cap its dosing.
Option C: Option C is incorrect: there is no drug-unique body surface area rule that mandates universal dose reduction.
Option D: Option D is incorrect: a fixed cumulative cardiac dose ceiling describes the anthracyclines, not vincristine.
6. Among the three vinca alkaloids in current use, vinorelbine occupies a distinct position with respect to neurotoxicity. How does vinorelbine's neurotoxicity compare to that of vincristine and vinblastine?
A) Vinorelbine produces intermediate neurotoxicity between vincristine and vinblastine, reflecting its relative selectivity for mitotic over axonal microtubules
B) Vinorelbine is the most neurotoxic vinca alkaloid, exceeding vincristine
C) Vinorelbine produces no neurotoxicity at any dose
D) Vinorelbine has identical neurotoxicity to vincristine because the mechanism is shared
E) Vinorelbine causes neurotoxicity only when combined with a taxane
ANSWER: A
Rationale:
Vinorelbine is a semisynthetic vinca alkaloid with relative selectivity for mitotic microtubules over axonal microtubules, which gives it intermediate neurotoxicity between vincristine (most neurotoxic) and vinblastine (least). Its own dose-limiting toxicity is myelosuppression (neutropenia). This graded ordering of neurotoxicity across the class, despite the shared binding mechanism, is the key discrimination point.
Option B: Option B is incorrect: vincristine, not vinorelbine, is the most neurotoxic vinca alkaloid.
Option C: Option C is incorrect: vinorelbine does cause neurotoxicity; it is intermediate, not absent.
Option D: Option D is incorrect: a shared mechanism does not make toxicity identical, because tissue distribution and microtubule selectivity differ among the agents.
Option E: Option E is incorrect: vinorelbine neurotoxicity is intrinsic to the drug and does not require combination with a taxane.
7. Understanding vincristine's metabolic handling explains its clinically important drug interactions. By which pathway is vincristine metabolized, and of which transporter is it a substrate?
A) Metabolized by CYP2D6 and a substrate of organic anion transporting polypeptide
B) Metabolized by CYP3A4 (cytochrome P450 3A4) and a substrate of P-glycoprotein (P-gp)
C) Eliminated unchanged by the kidney and not subject to transporter handling
D) Metabolized by CYP2C8 and a substrate of the breast cancer resistance protein only
E) Conjugated by UGT enzymes and not a substrate of any efflux transporter
ANSWER: B
Rationale:
Vincristine is metabolized by CYP3A4 (cytochrome P450 3A4) and is a substrate of P-glycoprotein (P-gp). This dual handling underlies its key interactions: CYP3A4 inhibitors such as azole antifungals increase vincristine exposure and neuropathy risk, and P-gp modulators alter its disposition. All three vinca alkaloids share P-gp and CYP3A4 handling as a class feature.
Option A: Option A is incorrect: vincristine is a CYP3A4 substrate, not principally CYP2D6, and its key efflux transporter is P-gp.
Option C: Option C is incorrect: vincristine undergoes hepatic CYP3A4 metabolism and is a transporter substrate, not eliminated unchanged renally.
Option D: Option D is incorrect: CYP2C8 is the major pathway for paclitaxel, not vincristine.
Option E: Option E is incorrect: vincristine is a P-gp substrate, so the claim that it is handled by no efflux transporter is wrong.
8. Vincristine can cause the syndrome of inappropriate antidiuretic hormone secretion (SIADH). What is the approximate incidence of SIADH with standard vincristine dosing?
A) Greater than 50% of treated patients
B) Approximately 25 to 30% of treated patients
C) Essentially never reported with standard dosing
D) Approximately 3 to 5% of treated patients, increasing with higher doses
E) Approximately 15 to 20% of treated patients
ANSWER: D
Rationale:
Vincristine-associated SIADH occurs in approximately 3 to 5% of patients with standard dosing, with the incidence increasing at higher doses or in patients with pre-existing hypothalamic dysfunction. It presents as euvolemic hyponatremia with inappropriately concentrated urine, and severe symptomatic hyponatremia is managed with fluid restriction and, when needed, careful hypertonic saline correction. Knowing it is an uncommon-but-recognized effect (a few percent) frames appropriate monitoring without overstating its frequency.
Option A: Option A is incorrect: SIADH is uncommon with vincristine, not affecting more than half of patients.
Option B: Option B is incorrect: roughly a quarter of patients overstates the true low-single-digit incidence.
Option C: Option C is incorrect: SIADH is a recognized vincristine effect, not essentially never reported.
Option E: Option E is incorrect: 15 to 20% overstates the approximate 3 to 5% incidence seen with standard dosing.
9. Paclitaxel and docetaxel are metabolized by different primary cytochrome P450 enzymes, a distinction that matters for predicting drug interactions. Which enzyme is the primary metabolizer of paclitaxel?
A) CYP1A2, with secondary metabolism by CYP2E1
B) CYP2D6, with secondary metabolism by CYP2C19
C) CYP2C8 (cytochrome P450 2C8), with a secondary contribution from CYP3A4
D) CYP3A4 exclusively, with no other P450 involvement
E) CYP2C9, with secondary metabolism by CYP2B6
ANSWER: C
Rationale:
Paclitaxel is primarily metabolized by CYP2C8 (cytochrome P450 2C8), which forms its major metabolite 6-alpha-hydroxypaclitaxel, with a secondary contribution from CYP3A4. This is the key discrimination from docetaxel, which is metabolized predominantly by CYP3A4. The practical consequence is that CYP2C8 inhibitors such as gemfibrozil are particularly relevant to paclitaxel, in addition to strong CYP3A4 inhibitors.
Option A: Option A is incorrect: CYP1A2 and CYP2E1 are not the paclitaxel pathways.
Option B: Option B is incorrect: CYP2D6 and CYP2C19 do not govern paclitaxel metabolism.
Option D: Option D is incorrect: although CYP3A4 contributes secondarily, the primary enzyme is CYP2C8, so exclusive CYP3A4 metabolism is wrong.
Option E: Option E is incorrect: CYP2C9 and CYP2B6 are not the principal paclitaxel-metabolizing enzymes.
10. In contrast to paclitaxel, docetaxel is metabolized predominantly by a single cytochrome P450 enzyme. Which enzyme predominantly metabolizes docetaxel?
A) CYP2C8, the same primary enzyme as paclitaxel
B) CYP2D6, making it sensitive to common antidepressant interactions
C) CYP1A2, with metabolism induced by tobacco smoke
D) CYP2C19, with metabolism affected by clopidogrel co-administration
E) CYP3A4 (cytochrome P450 3A4), making CYP3A4 inhibitors and inducers clinically important
ANSWER: E
Rationale:
Docetaxel is metabolized predominantly by CYP3A4 (cytochrome P450 3A4), so strong CYP3A4 inhibitors and inducers are clinically important and can substantially alter docetaxel exposure; docetaxel is also a P-glycoprotein substrate. This contrasts with paclitaxel, whose primary pathway is CYP2C8. Keeping the two taxanes' primary enzymes distinct is the discrimination this question targets.
Option A: Option A is incorrect: CYP2C8 is the primary pathway for paclitaxel, not docetaxel.
Option B: Option B is incorrect: docetaxel is not principally a CYP2D6 substrate.
Option C: Option C is incorrect: CYP1A2 (induced by tobacco smoke) does not govern docetaxel metabolism.
Option D: Option D is incorrect: CYP2C19 is not the predominant docetaxel pathway.
11. The hypersensitivity reaction caused by the Cremophor EL vehicle of conventional paclitaxel differs immunologically from classical drug anaphylaxis. Which statement correctly characterizes the Cremophor EL reaction?
A) It is a non-IgE-mediated (anaphylactoid) reaction that does not require prior sensitization and can occur on first exposure
B) It is a classical IgE-mediated reaction requiring prior sensitization to paclitaxel
C) It is a delayed type IV cell-mediated reaction appearing days after infusion
D) It is a serum sickness-type immune complex reaction peaking at 1 to 2 weeks
E) It is a direct cytotoxic (type II) reaction against red blood cells
ANSWER: A
Rationale:
The Cremophor EL reaction is a non-immunoglobulin E (non-IgE)-mediated, or anaphylactoid, reaction. It does not require prior sensitization and can occur on first exposure, typically within the first 10 minutes of infusion, with flushing, urticaria, bronchospasm, and hypotension. This distinguishes it from classical IgE-mediated anaphylaxis and is why a scheduled premedication regimen, rather than reliance on prior tolerance, is used.
Option B: Option B is incorrect: the reaction is not IgE-mediated and does not require prior sensitization.
Option C: Option C is incorrect: it is immediate (within minutes), not a delayed type IV cell-mediated reaction.
Option D: Option D is incorrect: it is not a serum sickness immune complex reaction with a delayed peak.
Option E: Option E is incorrect: it is not a type II cytotoxic antibody reaction against red cells.
12. Because nab-paclitaxel contains no Cremophor EL vehicle, its administration requirements differ from those of conventional paclitaxel. Which statement correctly describes nab-paclitaxel administration?
A) It requires the same three-drug hypersensitivity premedication and non-PVC tubing as conventional paclitaxel
B) It does not require the standard three-drug hypersensitivity premedication or non-PVC tubing, and is infused over about 30 minutes in normal saline
C) It requires a 24-hour continuous infusion to avoid albumin precipitation
D) It must be infused through a 0.22-micron filter to remove albumin aggregates, with mandatory corticosteroid premedication
E) It requires pretreatment with epinephrine because the albumin carrier itself is highly allergenic
ANSWER: B
Rationale:
Because the Cremophor EL vehicle is absent, nab-paclitaxel does not require the standard three-drug hypersensitivity premedication protocol or non-PVC tubing. It is reconstituted in normal saline and infused over about 30 minutes. Eliminating the vehicle, and with it the premedication and tubing precautions, is one of the clearest practical advantages of the albumin-bound formulation over conventional paclitaxel.
Option A: Option A is incorrect: those precautions exist because of Cremophor EL, which nab-paclitaxel lacks.
Option C: Option C is incorrect: nab-paclitaxel is given over roughly 30 minutes, not as a mandatory 24-hour infusion.
Option D: Option D is incorrect: there is no requirement for a special filter plus mandatory corticosteroid premedication driven by albumin aggregates.
Option E: Option E is incorrect: the albumin carrier is not the basis for hypersensitivity, and routine epinephrine pretreatment is not used.
13. Cabazitaxel carries a substantially higher rate of febrile neutropenia than docetaxel, which drives a specific supportive-care recommendation. Which measure is recommended for patients receiving cabazitaxel?
A) Routine prophylactic platelet transfusion before each cycle
B) Mandatory erythropoiesis-stimulating agent support to prevent anemia
C) Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) for all patients
D) Routine prophylactic broad-spectrum oral antifungal therapy as the principal protective measure
E) No supportive measures, because cabazitaxel myelosuppression is mild
ANSWER: C
Rationale:
Cabazitaxel produces febrile neutropenia at a rate substantially higher than docetaxel, so primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is recommended for all patients receiving it. This is the targeted supportive-care intervention matched to the drug's dominant hematologic risk. Cabazitaxel is also metabolized by CYP3A4, so interactions with strong CYP3A4 inhibitors or inducers require attention.
Option A: Option A is incorrect: the dominant risk is neutropenia, not thrombocytopenia requiring routine platelet transfusion.
Option B: Option B is incorrect: erythropoiesis-stimulating agents address anemia, not the febrile neutropenia that defines cabazitaxel's risk.
Option D: Option D is incorrect: the principal recommended measure is G-CSF, not routine prophylactic antifungal therapy.
Option E: Option E is incorrect: cabazitaxel myelosuppression is significant, with a high febrile neutropenia rate, so omitting support is inappropriate.
14. Ixabepilone in combination with capecitabine carries a specific contraindication related to hepatic function, based on increased toxic deaths observed in hepatically impaired patients. Which threshold defines this contraindication?
A) Ixabepilone plus capecitabine is contraindicated only when serum creatinine exceeds 2 mg/dL
B) The combination is contraindicated when the platelet count falls below 100,000 per microliter
C) The combination is contraindicated only in patients older than 75 years regardless of liver tests
D) Ixabepilone with capecitabine is contraindicated when AST (aspartate aminotransferase) or ALT (alanine aminotransferase) exceeds 2.5 times the upper limit of normal, or bilirubin exceeds 1.5 times the upper limit of normal
E) There is no hepatic contraindication; the combination is safe at any level of liver dysfunction
ANSWER: D
Rationale:
Hepatic impairment markedly increases ixabepilone exposure and toxicity. In combination with capecitabine, ixabepilone is contraindicated when AST (aspartate aminotransferase) or ALT (alanine aminotransferase) is above 2.5 times the upper limit of normal, or bilirubin is above 1.5 times the upper limit of normal, because of markedly increased toxic deaths observed in hepatically impaired patients in this combination in clinical trials. This is a hard liver-function threshold, not a relative caution.
Option A: Option A is incorrect: the contraindication is defined by hepatic transaminase and bilirubin thresholds, not a serum creatinine cutoff.
Option B: Option B is incorrect: it is a hepatic-function contraindication, not a platelet-count rule.
Option C: Option C is incorrect: it is defined by liver-test thresholds, not by age alone.
Option E: Option E is incorrect: a clear hepatic contraindication exists for the capecitabine combination, so claiming safety at any level of dysfunction is wrong.
15. Established vincristine neuropathy cannot be reversed by the supportive agents used to mitigate other chemotherapy toxicities. Which statement correctly describes the response of vincristine neurotoxicity to these agents?
A) It is rapidly reversed by granulocyte colony-stimulating factor given at the first sign of paresthesia
B) It does not improve with granulocyte colony-stimulating factor and is not rescued by leucovorin
C) It is fully reversed by leucovorin rescue, as with methotrexate toxicity
D) It is prevented entirely by routine pyridoxine supplementation in all patients
E) It resolves immediately upon administration of intravenous calcium and magnesium
ANSWER: B
Rationale:
Vincristine neurotoxicity does not improve with granulocyte colony-stimulating factor and is not rescued by leucovorin. Because it is cumulative and only partially reversible, prevention through serial neurologic monitoring and dose adjustment is far more effective than any attempt at pharmacologic rescue. This is the key foundational point: the supportive agents that counter other toxicities do not reverse vincristine neuropathy.
Option A: Option A is incorrect: granulocyte colony-stimulating factor supports neutrophil recovery and does not reverse neuropathy.
Option C: Option C is incorrect: leucovorin rescue applies to methotrexate, not vincristine neurotoxicity.
Option D: Option D is incorrect: routine pyridoxine does not reliably prevent vincristine neuropathy in all patients.
Option E: Option E is incorrect: calcium and magnesium infusion does not immediately resolve vincristine neuropathy.
16. After inadvertent intrathecal vinca alkaloid injection, a single rescue approach has been attempted with only rare partial survivors reported. Which intervention describes that attempted rescue protocol?
A) Immediate high-dose intravenous corticosteroids alone, which reliably halt the syndrome
B) Systemic plasmapheresis to remove the drug from the blood, which reverses the spinal injury
C) Oral activated charcoal and forced diuresis to enhance drug elimination
D) Hyperbaric oxygen therapy as definitive treatment
E) Immediate cerebrospinal fluid lavage (CSF exchange) combined with intrathecal instillation of fresh frozen plasma, with neurosurgical drain placement
ANSWER: E
Rationale:
The only attempted rescue, with rare partial survivors in case reports, is immediate cerebrospinal fluid (CSF) lavage, exchanging as much CSF as feasible with isotonic fluid through a neurosurgically placed ventricular drain, combined with intrathecal instillation of fresh frozen plasma (and, in some descriptions, glutamic acid). The rationale is that plasma proteins bind the vinca alkaloid and reduce free drug available to neurons. The evidence base is limited to case reports, complete recovery has not been documented, and the overriding clinical message remains error prevention rather than rescue.
Option A: Option A is incorrect: corticosteroids alone do not reliably halt this nearly uniformly fatal syndrome.
Option B: Option B is incorrect: systemic plasmapheresis does not reverse injury already occurring within the cerebrospinal fluid compartment.
Option C: Option C is incorrect: activated charcoal and forced diuresis address systemic drug, not the intrathecal compartment.
Option D: Option D is incorrect: hyperbaric oxygen is not the described rescue protocol for this injury.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.